ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non–muscle-invasive bladder cancer.
Authors
Mark Douglas Tyson (ORCID: https://orcid.org/0009-0001-5346-1404)
Michael B. Williams (ORCID: https://orcid.org/0000-0003-0836-2455)
Per Sandström (ORCID: https://orcid.org/0000-0002-8078-9528)
Corine Baayen
Vikram M. Narayan (ORCID: https://orcid.org/0000-0003-3731-4209)
Gautum Agarwal
Neal D. Shore (ORCID: https://orcid.org/0000-0001-5767-0548)
Kristian Vinter Juul (ORCID: https://orcid.org/0000-0002-2233-1746)
ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non–muscle-invasive bladder cancer.
Mark Douglas Tyson, Michael B. Williams, Per Sandström, Corine Baayen et al.
Citations
3 citations
Journal
Journal of Clinical Oncology
Topics
Bladder and Urothelial Cancer Treatments
Field-Weighted Citation Impact (FWCI)
6.02
article
ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non–muscle-invasive bladder cancer.
Mark Douglas Tyson, Michael B. Williams, Per Sandström, Corine Baayen, Vikram M. Narayan, Gautum Agarwal, Neal D. Shore, Kristian Vinter Juul, Evan R. Goldfischer
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 43(16_suppl)
Institutions
Emory University (US), Eastern Virginia Medical School (US), Urology of Virginia (US), Mayo Clinic Hospital (US), Ferring Pharmaceuticals (Denmark) (DK), Carolina Urologic Research Center (US)